ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.9785
0.21%
Brent Oil
83.605
0.08%
Bitcoin
57,151.19
-1.89%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) Noticias

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IONS
FechaHoraFuenteTítuloSímboloCompañía
25/04/202406:00PR Newswire (US)Ionis Publishes 2023 Corporate Responsibility ReportNASDAQ:IONSIonis Pharmaceuticals Inc
23/04/202406:05PR Newswire (US)Ionis to hold first quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
07/04/202408:48PR Newswire (US)Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
01/04/202406:05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
28/03/202406:05PR Newswire (US)Ionis to hold olezarsen Phase 3 data webcastNASDAQ:IONSIonis Pharmaceuticals Inc
25/03/202407:18PR Newswire (US)Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingNASDAQ:IONSIonis Pharmaceuticals Inc
13/03/202406:00PR Newswire (US)Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHNASDAQ:IONSIonis Pharmaceuticals Inc
06/03/202406:30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:IONSIonis Pharmaceuticals Inc
04/03/202418:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
29/02/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
29/02/202408:05PR Newswire (US)Ionis announces new chief global product strategy officer to lead next phase of commercial growthNASDAQ:IONSIonis Pharmaceuticals Inc
21/02/202406:00PR Newswire (US)Ionis reports fourth quarter and full year 2023 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
20/02/202409:39Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
16/02/202415:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
15/02/202406:00PR Newswire (US)Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
14/02/202409:04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IONSIonis Pharmaceuticals Inc
13/02/202405:09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
08/02/202406:00PR Newswire (US)Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathyNASDAQ:IONSIonis Pharmaceuticals Inc
07/02/202406:05PR Newswire (US)Ionis to hold fourth quarter and full year 2023 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
22/01/202406:00PR Newswire (US)Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedemaNASDAQ:IONSIonis Pharmaceuticals Inc
08/01/202406:03PR Newswire (US)Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseasesNASDAQ:IONSIonis Pharmaceuticals Inc
21/12/202318:38Dow Jones NewsIonis Pharmaceuticals, AstraZeneca Get FDA Approval for Rare Genetic Disease TreatmentNASDAQ:IONSIonis Pharmaceuticals Inc
21/12/202317:55PR Newswire (US)WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosisNASDAQ:IONSIonis Pharmaceuticals Inc
20/12/202306:05PR Newswire (US)Ionis to present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IONSIonis Pharmaceuticals Inc
18/12/202315:56Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
18/12/202315:01PR Newswire (US)Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedemaNASDAQ:IONSIonis Pharmaceuticals Inc
14/12/202315:05PR Newswire (US)Ionis announces the appointment of Michael Yang to Board of DirectorsNASDAQ:IONSIonis Pharmaceuticals Inc
24/11/202312:31Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:IONSIonis Pharmaceuticals Inc
16/11/202307:00GlobeNewswire Inc.Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental EpilepsiesNASDAQ:IONSIonis Pharmaceuticals Inc
11/11/202310:30PR Newswire (US)Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IONS

Su Consulta Reciente

NASDAQ
MSFT
Microsoft
NASDAQ
AMZN
Amazon.com
USOTC
BASFY
BASF (QX)
COIN
ETHUSD
Ethereum
NYSE
NKE
Nike
USOTC
BNPQY
BNP Paribas (QX)
COIN
SOLUSD
Solana
NYSE
KO
Coca Cola
NYSE
VZ
Verizon Communications
PM
XAUUSD
Gold vs US Dollar
NYSE
JPM
JP Morgan Chase
NYSE
DIS
Walt Disney
NASDAQ
TSLA
Tesla
FX
EURMXN
Euro vs MXN
NASDAQ
GOOGL
Alphabet
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados